SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CytRx Oncology Corp – ‘8-K’ for 6/2/07

On:  Monday, 6/4/07, at 4:35pm ET   ·   For:  6/2/07   ·   Accession #:  950144-7-5451   ·   File #:  0-51534

Previous ‘8-K’:  ‘8-K’ on 5/11/07 for 5/7/07   ·   Next:  ‘8-K’ on / for 6/7/07   ·   Latest:  ‘8-K’ on 6/18/08 for 6/16/08

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/04/07  CytRx Oncology Corp               8-K:8,9     6/02/07    2:25K                                    Bowne of Atlanta Inc/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Innovive Pharmaceuticals, Inc.                      HTML     12K 
 2: EX-99.1     Press Release                                       HTML     15K

8-K   —   Innovive Pharmaceuticals, Inc.

This is an HTML Document rendered as filed.  [ Alternative Formats ]

  Innovive Pharmaceuticals, Inc.  
 

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2007
INNOVIVE PHARMACEUTICALS, INC.
 
(Exact name of registrant as specified in its charter)
         
Delaware   000-51534   74-3123261
 
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer ID Number)
555 Madison Avenue, 25th Floor, New York, New York 10022
 
(Address of principal executive offices)                 (Zip Code)
Registrant’s telephone number, including area code           (212) 716-1810          
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01. Other Events.
On June 2, 2007, Innovive Pharmaceuticals, Inc. issued a press release announcing that additional Phase I data on INNO-406 for treatment of Gleevec-resistant or intolerant chronic myelogenous leukemia was presented in a poster at the American Society of Clinical Oncology Annual Meeting in Chicago. The press release is attached as an exhibit to this report.
Item 9.01. Financial Statements and Exhibits.
(c)     Exhibits
     
Exhibit    
Number   Description of Document
 
    
99.1
  Press release dated June 2, 2007

 

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
 
  INNOVIVE PHARMACEUTICALS, INC.
 
    
Date: June 4, 2007
  /s/ Steven Kelly
 
   
 
  Steven Kelly
President and Chief Executive Officer

 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:6/4/07424B3
For Period End:6/2/07
 List all Filings 
↑Top
Filing Submission 0000950144-07-005451   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., Apr. 17, 10:15:09.1pm ET